Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358143

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358143

Global and China Osteoporosis Drugs Market, By Drug Type, By Geography

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The Global and China Osteoporosis Drugs Market is estimated to be valued at US$ 14.6 Bn in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 14.6 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.90% 2030 Value Projection: US$ 19.1 Bn
Global and China Osteoporosis Drugs Market Share (%), by Drug Type, 2023
Global and China Osteoporosis Drugs Market - IMG1

Osteoporosis is characterized by a decrease in the density and quality of bones, which frequently leads to broken wrist, hip, and spine bones. Various factors responsible for osteoporosis include, genetic factors; low intake of calcium, magnesium, and vitamin D; eating disorders such as anorexia, inactivity & immobility, and excessive alcohol intake. Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures). Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Market Dynamics

The increasing research & development activities are attributed to the growth of the global and China osteoporosis drugs market. For instance, according to a study shared by Contemporary OB/GYN- a monthly publication dedicated to translating science into clinical practice, on March 10, 2023, Hormone therapy (HT) for osteoporosis can increase lumbar spine bone mineral density (BMD) and prevent bone loss in post menopausal women. The large cross-sectional study showed that current and prior use of multiple types of hormone therapies, including combined hormone contraception used in premenopausal women and menopause hormone therapies, were linked with bone protection in postmenopausal women and that these effects persisted after discontinuation of treatment. The article also concluded that stopping HT and varying doses impact bone health, including fracture risk.

Key features of the study:

  • This report provides an in-depth analysis of the global and China osteoporosis drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global and China osteoporosis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck KGaA, Lilly, Procter & Gamble, Enzo Biochem Inc., Sanofi, Novartis AG, Wyeth Nutrition (A subsidiary of Pfizer Inc.), F. Hoffmann-La Roche Ltd, GSK plc, UCB S.A., Amgen Inc., BeiGene, Inc., Bone Biologics Corp, TEIJIN LIMITED, Eden Biologics (Formerly known as JHL Biotech Inc.), Keros Therapeutics, and Taro Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global and China osteoporosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global and China osteoporosis drugs market.

Detailed Segmentation:

  • Global and China Osteoporosis Drugs Market, By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
  • Global and China Osteoporosis Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global and China Osteoporosis Drugs Market, By Distribution Channel:
    • Hospitall Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Global and China Osteoporosis Drugs Market, By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Merck KGaA
    • Lilly
    • Procter & Gamble
    • Enzo Biochem Inc.
    • Sanofi
    • Novartis AG
    • Wyeth Nutrition (A subsidiary of Pfizer Inc.)
    • F. Hoffmann-La Roche Ltd
    • GSP plc
    • UCB S.A.
    • Amgen Inc.
    • BeiGene, Inc.
    • Bone Biologics Corp
    • TEIJIN LIMITED
    • Eden Biologics (Formerly known as JHL Biotech Inc.)
    • Keros Therapeutics
    • Taro Pharmaceutical Industries Ltd.
Product Code: CMI4018

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global and China Osteoporosis Drugs Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global and China Osteoporosis Drugs Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Selective Estrogen Receptor Modulators (SERMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Rank Ligand (RANKL) Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global and China Osteoporosis Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global and China Osteoporosis Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global and China Osteoporosis Drugs Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • China
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018- 2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Lilly
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Procter & Gamble
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Enzo Biochem Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wyeth Nutrition (A subsidiary of Pfizer Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Hoffmann-La Roche Ltd
  • GSP plc
  • UCB S.A.
  • Amgen Inc.
  • BeiGene, Inc.
  • Bone Biologics Corp
  • TEIJIN LIMITED
  • Eden Biologics (Formerly known as JHL Biotech Inc.)
  • Keros Therapeutics
  • Taro Pharmaceutical Industries Ltd.

10. Section

  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!